Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

FOUND: Sldb - What They Never Told You

What is Tottenham Hotspur billionaire Joe Lewis accused of?

Joe Lewis has been accused of 16 counts of securities fraud in the US. We examine the allegations through the companies he invested in

The Guardian - UK · Jul 26, 2023

Looking Into Solid Biosciences's Return On Capital Employed

Solid Biosciences (NASDAQ:SLDB) brought in sales totaling $1.93 million during Q1 according to data provided by Benzinga Pro. However, earnings decreased 36.1%, resulting in a loss of $25.33 million.

Benzinga · May 2, 2022

Duchenne Player Solid Biosciences Realigns Pipeline Strategy, Cuts Staff By 35%

Solid Biosciences Inc (NASDAQ: SLDB) is shaving down its pipeline, updating its operations strategy to prioritize the advancement of AAV-mediated gene transfer therapies, SGT-001 and SGT-003.

Benzinga · Apr 27, 2022

From analysis to the latest developments in health,
read the most diverse news in one place.

Recap: Solid Biosciences Q1 Earnings

Solid Biosciences (NASDAQ:SLDB) reported its Q1 earnings results on Wednesday, April 27, 2022 at 06:00 AM. Here's what investors need to know about the announcement.

Benzinga · Apr 27, 2022

Earnings Outlook For Solid Biosciences

Solid Biosciences (NASDAQ:SLDB) is set to give its latest quarterly earnings report on Wednesday, 2022-04-27. Here's what investors need to know before the announcement. Analysts estimate that Solid Biosciences will report an earnings per share (EPS) of $-0.18.

Benzinga · Apr 26, 2022

Solid Biosciences's Return On Capital Employed Insights

Benzinga Pro data, Solid Biosciences (NASDAQ:SLDB) reported Q4 sales of $3.15 million. Earnings fell to a loss of $18.61 million, resulting in a 3.49% decrease from last quarter.

Benzinga · Mar 16, 2022

Solid Biosciences Posts Two-Year Efficacy, Safety Data From Duchenne Gene Therapy Trial

Solid Biosciences Inc (NASDAQ:SLDB) has reported two-year interim efficacy and safety data from the first three patients treated with SGT-001 in the high dose (2E14 vg/kg) cohort as part of IGNITE DMD. Results suggest durable benefit 24-months post-administration of SGT-001 compared to natural history, consistent with results reported at the 12-month and 18-month…

Benzinga · Mar 14, 2022

Read news from The Economist, FT, and more,
with one subscription

Recap: Solid Biosciences Q4 Earnings

Solid Biosciences (NASDAQ:SLDB) reported its Q4 earnings results on Monday, March 14, 2022 at 06:00 AM. Here's what investors need to know about the announcement.

Benzinga · Mar 14, 2022

Coverage From

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.